← Back to headlines
H.C. Wainwright Reiterates Buy on Beam Therapeutics After FDA Expedited Approval
H.C. Wainwright has reiterated its 'Buy' rating on Beam Therapeutics (BEAM) following the FDA's expedited approval of BEAM-302.
15 Feb, 13:41 — 15 Feb, 13:41
ℹOnly 1 source covers this story
